Dr. Roy H. Larsen has a Ph.D. and postdoctoral experience in radiopharmaceutical chemistry from University of Oslo, Norway and Duke University, USA, respectively. Dr. Larsen has long experience within drug development and business. He was the main founder of Algeta ASA (founded in 1997, acquired by Bayer in 2014), and he served as Managing Director and later Chief Scientific Officer in Algeta ASA from 1997–2006, where he also was a board member from 1997-2003. He is also one of the founders of Nordic Nanovector ASA (2009), and Oncoinvent AS (2010). Roy H. Larsen was chairman of the board in Nordic Nanovector from 2009 to 2014, and a member of the board until 2016. Dr. Larsen works as a consultant and founder through Sciencons AS.
Dr. Thóra J. Jónasdóttir is a DVM, with Ph.D. and postdoctoral research experience within cancer and clinical trials in mouse models and dogs with spontaneous cancers. Dr. Jónasdóttir was the CEO of Oncoinvent AS from the start-up in 2010 to August 2013, along with a part position at the Norwegian University of Life Sciences as head of the canine cancer research group (until 2015) and as a supervisor of Ph.D. students. Since August 2013 she has worked as the Veterinary Officer for Pet Diseases and Animal Welfare at Icelandic Food and Veterinary Authority. Dr. Jónasdóttir is one of the founders of Oncoinvent AS (2010).
Born 1952. BSc Chemistry & Biology 1976, MD 1979 and PhD in 1989, University of Oslo, Norway.
Certified clinical specialist in Clinical Oncology.
2008-2022 Professor of Clinical Oncology (Tenure position), University of Oslo, Norway and from January 2023, Professor emeritus.
2004-present Senior Consultant Oncologist, Department of Oncology (now 50% part time position), The Norwegian Radium Hospital, Oslo University Hospital.
“Serial entrepeneur” being a co-founder of Algeta AS, Nordic Nanovector AS, Oncoinvent AS and Nucligen/ArtBio Inc.
Ludvik Sandnes has more than 40 years of experience from international corporate finance, asset management and investment banking from Norfund, The Royal Bank of Scotland, BDO Noraudit, PwC Financial Advisors, Christiania Bank, UNI Storebrand, Orkla Borregaard, Den Norske Creditbank and Statoil. He has experience from more than 20 boards including chairman of Nordic Nanovector. Current board positions also include Oslo Cancer Cluster. He has a Bachelor of Commerce and a degree as Certified European Financial Analyst (AFA) from the Norwegian School of Economics and Business Administration, NHH.
Petter J. Fjellstad is a Norwegian citizen with an education from Yale University (BA cum laude, Distinction in the Major, 1983) and Harvard Business School (MBA 1985). He has experience from McKinsey & Co in both Scandinavia and the USA.
In the nineties, he was CEO of Dyvi AS. Fjellstad himself started and was an early investor in a number of companies: 1) CRI as, a tech company that went public in 1997 on the Oslo Stock Exchange. 2) Vision Park (computer game) which went public in Stockholm. 3) Medisinsk Ustyr as, a med-tec company which he turned around and later sold. 4) Dropzone as, an online based distributor for software and PCs which in 2012 was sold to Atea. He is an early investor in a number of other businesses in the USA and Norway.
In 2007, he founded Grand Haven Capital, a hedge fund based in Switzerland where he was a manager. Fjellstad is, among other things, chairman of Next Biometrics, listed on Oslo Børs, and Alva Industries, a start-up. In all these situations he has been instrumental in raising money. In his career, he has held several board positions in both listed and private companies.
Leiv Askvig has had an international career in the financial industry, having held executive positions and served on the board of numerous companies and organizations, including 19 years in Sundt AS were he was CEO for 17 years, 15 years at Sundal Collier & Co where he was CEO for 5 years, and 5 years as chairman of the board at Oslo Børs VPS Holding ASA. Askvig is currently an Investment Advisor of Sundt AS. He holds board positions with Civita, Eiendomsspar, Ultimovacs AS and Toluma AS. Leiv Askvig has a BBA from BI in Norway and AMP from Harvard Business School.
Born 1969. She obtained her MD in 1997, PhD in 2013, and Master in Health and Administration in 2017, University of Oslo, Norway.
Certified clinical specialist in Nuclear Medicine. From 2023 appointed Head of the Intervention Centre, Division of Technology and Innovation, Oslo University Hospital with a Professor 2 position, Faculty of Medicine, University of Oslo.
2014 – 2023 Head of Section of Nuclear Medicine and Research, Dept. of Nuclear Medicine, Oslo University Hospital, Norway
Worked at Oncoinvent AS since 2019 as Senior Quality Assurance Officer and Qualified Person (QP).
Have a cand. pharm. degree (M.Sc.) from the University of Tromsø, a certificate of Advanced Studies (CAS) in Radiopharmaceutical Chemistry/Radiopharmacy from Eidgenössische Technische Hochschule Zürich.
Has worked in pharma industry for 16 years and with radiopharmaceuticals for 10 years.
Has worked in Pharmacies for 7 years in various functions including leading positions.
+47 488 68 863
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.